Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

BACKGROUND AND AIMS: Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We report integrated analyses of infections in the Phase [P]2 and P3 OCTAVE programmes. METHODS: Three cohorts were analysed: Induction [P2/3 induction studies]; Maintenance [P3 mainten...

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin L, Loftus, Edward V, Baumgart, Daniel C, Reinisch, Walter, Nduaka, Chudy I, Lawendy, Nervin, Chan, Gary, Mundayat, Rajiv, Friedman, Gary S, Salese, Leonardo, Thorpe, Andrew J, Su, Chinyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218715/
https://www.ncbi.nlm.nih.gov/pubmed/33245746
http://dx.doi.org/10.1093/ecco-jcc/jjaa233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218715/
https://www.ncbi.nlm.nih.gov/pubmed/33245746
http://dx.doi.org/10.1093/ecco-jcc/jjaa233

Ejemplares similares